Targeting p53-p21 signaling to enhance mesenchymal stem cell regenerative potential

Area of Science:

• Regenerative Medicine
• Stem Cell Biology
• Molecular Biology

Background:

• Mesenchymal stem cells (MSCs) possess self-renewal and differentiation capabilities, making them promising for regenerative medicine.
• Therapeutic applications of MSCs are often limited by senescence, reduced proliferation, and apoptosis.
• The p53-p21 pathway plays a crucial role in MSCs, balancing genomic stability with senescence and regenerative capacity.

Purpose of the Study:

• To review the role of the p53-p21 pathway in MSC biology.
• To explore strategies for targeting p53-p21 signaling to enhance MSC function.
• To discuss the potential of modulating this pathway for improved regenerative medicine outcomes.

Main Methods:

• Review of recent advances in targeting p53-p21 signaling in MSCs.
• Discussion of pharmacological agents (e.g., PFT-α, antioxidants) and genetic tools (CRISPR-Cas9, RNAi).
• Analysis of the interplay between p53-p21 and other signaling pathways (Wnt/β-catenin, MAPK).

Main Results:

• Targeting p53-p21 signaling can delay senescence and improve MSC proliferation and differentiation.
• Pharmacological agents and genetic tools can effectively modulate p53-p21 activity.
• Combinatorial therapies show promise for enhancing MSC resilience and regenerative potential.

Conclusions:

• Modulating the p53-p21 pathway is a key strategy to overcome MSC limitations.
• Optimizing MSC functionality through p53-p21 targeting can lead to advanced regenerative therapeutics.
• Addressing senescence, proliferation, and stress resilience is crucial for harnessing MSC potential.